97 results
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
financial performance of Vir Biotechnology, Inc. (the “Company” or “Vir”); the Company’s strategy and plans; capital allocation; financial and operating … billion-dollar mergers and acquisitions Served as a member of Bayer’s Executive Committee, and EVP and Global Head of Strategy, BD&L and Open
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
include, but are not limited to, statements regarding Vir’s strategy and plans; Vir’s cash balance; Vir’s financial guidance; Vir’s future financial
8-K
EX-99.1
VIR
Vir Biotechnology Inc
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
to, statements regarding Vir’s strategy and plans; whether Drs. Bischofberger and Farid are elected to the Board by the Company’s stockholders at the 2024
8-K
EX-99.1
qaeo8xl6a6 2sol
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
yw9p 2eqx7p7oue
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
S-3ASR
nna34
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
dpht6ut0yl3xl782j2zr
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
6knv1vp5 0dqkp
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
8yoz0v572sig 9v4v7
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
ahpt2 e6sju
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
692c3jv v3i
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
sp9u83 cfxaj
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm